United States: Making The Biosimilar Business Case—Exploring The Interface Between Economics And Patent Law
Last Updated: January 23 2017

This first webcast of our series will explore both the economic market factors of the biosimilar world and patent strategies, and how they impact target selection for biologics and biosimilars. In contrast to the development of generic small molecules, it has been reported that it takes seven to eight years to develop a biosimilar at a cost of between $100 million and $250 million. The identification of targets requires detailed analyses of the marketplace, patent portfolios, long-term strategies for optimizing and navigating patent portfolios, and technical and regulatory issues in developing a biologic or biosimilar.

The panel will discuss factors for consideration in strategic selection and protection of biologic products, including:

  • The scope of patent protection available for biologic products
  • The impact of differences in patent protection in the United States and Europe
  • Deciding between patent and trade secret protection
  • Research, manufacturing and supply considerations, such as safe harbor protection, the ease of potential design-arounds, and potential infringement liability when a patented combination is done outside of the United States or an imported product is made by patented process performed outside of the United States
  • Considerations for the use of post-grant proceedings before the United States Patent and Trademark Office and district court litigation to clear the patent thicket, including the alternative, sequential, or concurrent timing of those proceedings

Register: There is no charge to attend this program. Please register by Monday, January 23, 2017. Webinar access and dial-in information will be sent upon registration.

Scheduling Conflict? Finnegan records all hosted webinars. To view the recorded program, simply register for the webinar and you will receive an access link shortly after the live program is complete.



Basil "Bill" J. Lewris


Leslie A. McDonell

Linda A. Wadler


Tuesday, January 24, 2017


10:00 - 11:00 a.m. PST

1:00 - 2:00 p.m. EST

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Press Releases from this Firm
Recent Content from this Firm
By Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
By Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
By John Paul, Brian Kacedon, Robert MacKichan III
By John Paul, Brian Kacedon, Sean Damon
By John Paul, Brian Kacedon, Cecilia Sanabria
By Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
By Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
By Ashley Winkler, Kara Specht
By Michael Flibbert, Pier DeRoo
By Jack Li
Font Size: